OPDP Frequently Asked Questions (FAQs) (2023)

Consumer-Directed Advertisements
Drug of Choice
Drug Name Size
Launch Information
Package Inserts
Post-marketing Reporting
Presentation of Information
Press Releases
Pre-distribution Submissions
Reminder Advertisements
Miscellaneous Questions

Consumer-Directed Advertisements

What are the general requirements for prescription drug advertisements directed toward consumers?

The same statute and regulations apply regardless of the audience targeted by a prescription drug advertisement. The Federal Food, Drug, and Cosmetic Act (the FD&C Act) requires that all drug advertisements contain (among other things) information in brief summary relating to side effects, contraindications, and effectiveness. Because of this statutory wording, this requirement has become known as the brief summary. Typically, print advertisementsinclude a reprinting of the risk-related sections of the product's FDA-approved labeling (also called full prescribing information or the package insert). Sponsors, however, can write this risk information in language appropriate for the targeted audience; FDA encourages this approach. In order to present useful information to consumers, FDA has recommended that certain information be provided in the brief summary while other information may be omitted. Guidance for Industry: Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Human Prescription Drugs (PDF)

In addition to the specific disclosure requirements, advertisements cannot be false or misleading or omit material facts. They also must present a fair balance between effectiveness and risk information. FDA has consistently required that appropriate communication of effectiveness information includes any significant limitations to product use.

How do prescription drug broadcast advertisements differ from print advertisements?

Current regulations specify two requirements that all prescription drug broadcast advertisements must meet. First, broadcast advertisements must include the product's most important risk-related information in the audio or audio and visual parts of the advertisement. This is sometimes called the major statement.Second, broadcast advertisements must contain either a brief summary of the advertised product's risk information, or alternatively, make adequate provision for disseminating the product's approved labeling in connection with the ad. Thus, the regulations for broadcast advertisements recognize broadcast's inherent limitations by providing an alternative mechanism for meeting the FD&C Act's information disclosure requirement.

What needs to be included as part of the major statement requirement?

The major statement must include all of the most important risk information related to the product. Because risks vary from product to product, the amount of information disclosed for any particular product to meet this requirement will vary as well.

Does FDA intend to do anything about the brief summary information? I've heard a lot of concerns about its value for consumers.

FDA has also heard concerns about the lack of value of thecurrent approaches to present therequired information from some individuals and groups. It has heard from others that consumers should get full disclosure of risk information. The agency encourages product sponsors to provide consumers with non-promotional, consumer-friendly information consistent with product labeling, along with the information required by the FD&C Act and the regulations. As mentioned above, in the case of print advertisements, FDA encourages sponsors to write their product brief summaries in consumer-friendly language and to follow other guidance, as available.

Drug of Choice

May the phrase "drug of choice" be used in advertising or promotional labeling?

The phrase "drug of choice," or any similar phrase or presentation, used in an advertisement or promotional labeling would make a superiority claim and, therefore, the advertisement or promotional labeling would requireevidence to support that claim.

Drug Name Size

Does the established or proprietary name in the advertisement or brief summary have to be any particular size?

No, but the regulations specify size in sections 201.10(g)(2) and 202.1(b)(2) which state:
"The established name shall be in printed letters that are at least half as large as the letters comprising the proprietary name or designation with which it is joined, and the established name shall have a prominence commensurate with the prominence with which such proprietary name or designation appears, taking into account all pertinent factors, including typography, layout, contrast and other printing features."

(Video) Office of Prescription Drug Promotion (OPDP) - Core Launch Review Process

Does "half as large" refer to point size or actual type size?

OPDP has interpreted "half as large" to be actual size, not point size, of upper and lower case letters in the proprietary and established drug names.


May an advertisement or labeling piece include the phrase "FDA-approved"?

Yes, if the manufacturer or sponsor has received a letter stating that the product has been approved. Effective on the date of implementation, the Food and Drug Administration Modernization Act of 1997 eliminated Section 301(l) of the Federal Food, Drug, and Cosmetic Act that prohibited "The using . . . of any representation or suggestion that approval of an application with respect to such drug or device is in effect . . . ."


How long may the word "new" be used in promotional labeling and advertisements for a newly approved product, indication, or dosage form?

OPDP generally considers that "New" is an accurate description of the marketing phase for six months from the time a product is initially marketed. This should be distinguished from the time the product is cleared by FDA for marketing.

Launch Information

Have there been any updates or improvements to the core launch review process?

OPDP has evaluated trends in core launch submissions over the past several years. We have also evaluated our internal business processes considering trends in prescription drug promotion submissions. In order to provide timely feedback to firms, ensure submissions are complete and reviewable, and maximize use of FDA’s resources, OPDP has added a 5-business day core launch screening period to the launch review process and provided additional clarification on what OPDP considers to be core launch materials for purposes of its review.

What is the 5-day business day core launch screening period that will occur prior to the beginning of a core launch review?

Upon receipt of a submission requesting comments on proposed core launch materials, OPDP review and project management staff will conduct a 5-business day administrative content review to determine if the submission is complete, annotated to clearly identify the source of support for each claim, and consistent with core launch parameters. Day 1 of the 5-business day core launch screening period will begin on the first business day on which the core launch submission is received by OPDP.

What information will OPDP communicate as a result of the 5-business day core launch screening period?

OPDP will notify the firm by the end of the 5-business day core launch screening period if the core launch needs an amendment, additional reference materials, or the materials are non-core launch or non-launch. Amendments and reference documents will be assigned a new 5-business day core launch screening period once received by OPDP. If there are no reasons why core launch will not commence and the core launch submission is complete and acceptable for review, OPDP will NOT contact the firm, and our review of the core launch submission will begin on the 6th business day after the core launch submission was received.

What factors will OPDP consider when assessing if materials qualify as “core” launch?

What OPDP considers to be core launch materials can be found in the guidance titled, “Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs” (OPDP Electronic Submission Guidance – Section IV.C.1).

In addition, to be within the bounds of what OPDP intends to review under the processes we describe for “core launch advisories”, those submitted materials should:

  • Be limited to claims and presentations based solely on the information contained in the PI, information from the pivotal/registration trials, or publications directly related to those trials.
  • Be a true representation of the core introductory messaging for the product (i.e., not a mock-up piece that includes all potential claims a firm is considering for its promotional campaign).

What does an annotated core launch piece look like?

Section VI.F.3 of the OPDP Electronic Submission Guidance describes how to annotate promotional materials. Sections VI.G.2 and VI.H of the OPDP Electronic Submission Guidance describe annotating product labeling and references, respectively. We have also included a link to an annotated mock promotional piece as an example.

If a firm’s piece presents information not contained in the PI but that may be consistent with the PI, will FDA consider the core launch advisory submission to be complete if it does not include a CFL analysis?

Yes. A core launch advisory submission will be considered complete even if it does not include analyses of the three factors described in the guidance titled, “Medical Product Communications That Are Consistent With the FDA-Required Labeling — Questions and Answers Guidance for Industry” (CFL Guidance). However, if a sponsor chooses to submit its analysis in order to support the sponsor’s assessment that the claims and/or presentations are consistent with the FDA-approved labeling, FDA will consider it.

(Video) Ready to Launch: Essentials of Submitting Initial Materials to OPDP (12of15) REdI– May 29-30, 2019

A CFL analysis can be provided within the annotated version of the promotional piece. A mock promotional piece annotated to include a CFL analysis is linked here as an example.

If a claim or presentation is supported directly by the PI, please reference or annotate to the PI.

How do consults influence core launch advisory response times from OPDP?

Firms are reminded that if a launch advisory submission is designated as “core,” the 45-calendar day response goal does not include consultation time outside of OPDP. Materials submitted with claims and presentations not derived completely and directly from the FDA-required labeling for the product may require consultation with other experts within the FDA, which will result in a longer turnaround time for comments from OPDP. Therefore, firms should build longer overall response times into their launch implementation plans if they ask for advisory comments on core launch materials that include such claims and presentations.

How does OPDP prioritize the review of non-core launch materials?

Submission of Non-core launch materials for advisory comments is addressed Section IV.C of the OPDP Electronic Submission Guidance. While we understand that all materials are a priority for sponsors, OPDP considers non-core launch materials to be a lower priority than core launch materials. OPDP recommends that firms apply our comments on the core launch materials to non-core launch materials.


Q: Would a launch promotional submission with disease state information based on references that are not the PI or registration trials/publications be considered core?

A: A launch submission that includestargetedclaims orpresentationsofdisease state informationthat implya benefit orsafetyclaim forthe promoteddrug should be supported by information derived from the PI, information from the pivotal/registration trials, or publications directly related to those trials to be considered core. General information about a disease state accompanied by annotations to publications such as widely-recognized disease guidelines or scientific or medical reference texts may be included in a core launch submission.


Q: Are CBER’s Advertising and Promotional Labeling Branch (APLB) and CDRH following the 5-business day core launch screening period as well?

A: The 5-business day core launch screening period was developed for submissions requesting comments from OPDP on proposed core launch materials.If you have questions or need information about launches for APLB or CDRH products, please contact them directly.


Q: How does FDA determine the receipt date that initiates the 5-business day core launch screening?

A: Please refer to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – Receipt Dates for more information on how FDA determines the date of receipt for regulatory submissions.

Package Inserts

Does it matter where a package insert is placed on a labeling piece, such as on a calendar or a brochure with a pouch?

The package insert is required to accompany the labeling piece.

Are package inserts required in all labeling pieces for products that are the same except for different strengths or dosages?

Yes. Even though products may be very similar, package inserts may be different for different dosage forms or different delivery systems for the same drug. The regulations require a package insert for each dosage form and delivery system for which claims appear in the promotional labeling piece. Some drug products, however, have multi-dosage form package inserts. In those cases, the same package insert could be attached to each piece, even if the dosage forms or delivery systems were different.

(Video) Little-known Facts about Non Therapeutic Uses of Drugs and Devices | Patti Zettler

Does a package insert in another language also have to be submitted in English?

Yes. Package inserts have to be submitted in English and not only in the foreign language.

Postmarketing Reporting

Where do the regulations state the requirement for submitting prescription drug advertisements and labeling?

Under 21 C.F.R. 314.81(b)(3)(i):

Section 314.81 Postmarketing reports.


(b) Reporting requirements. The applicant shall submit to the Food and Drug Administration at the specified times two copies of the following reports:


(3) Other reporting--(i) Advertisements and promotional labeling. The applicant shall submit specimens of mailing pieces and any other labeling or advertising devised for promotion of the drug product . . . .

(See Selected Provisions of the Regulations for the entire paragraph.)

When do promotional materials need to be submitted to OPDP?

Pursuant to 314.81(b)(3)(i), submissions must be made " . . . at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement for a prescription drug product."

Do all promotional materials for prescription drugs have to be submitted to OPDP?

The regulations for submitting materials apply to holders of NDAs, ANDAs, and antibiotic applications. Manufacturers of pre-1938 products and products that have been declared "not new drugs" are not required to submit specimens. All products have labels and prescribing information, however, and products without approved labeling have permitted labeling. Permitted labeling indicates FDA agrees with the label or labeling and permits its use. A manufacturer of a product with "permitted" labeling is responsible for assuring that advertisements and promotional labeling pieces are consistent with the product labeling.

What form should applicants use to submit materials to FDA?

Form FDA 2253 Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use.

How can I obtain a Form FDA-2253?

Form FDA-2253

To whom should I send the materials?

(Video) Post-Approval Submission of Promotional Materials to the OPDP - REdI 2020

Please see draft guidance entitled Providing Regulatory Submissions in Electronic and Non-Electronic Format - Promotional Labeling and Advertising Materials for Human Prescription Drugs for information on how to submit. FDA began accepting eCTD submissions using the new M1 specifications Juneof 2015.

Who is responsible for submitting a Form FDA-2253 if the manufacturer and distributor are different companies?

Either company may submit the specimens, however, the applicant is ultimately responsible for compliance with 21 CFR 314.81(b)(3).

Presentation of Information

Can the layout or the way information is presented affect whether an advertisement or labeling piece is in compliance with the regulations?

Yes, 21 CFR 202.1(e)(7)(viii) states that an advertisement may be false, lacking in fair balance, or otherwise misleading if it:

"Fails to present information relating to side effects and contraindications with a prominence and readability reasonably comparable with the presentation of information relating to effectiveness of the drug, taking into account all implementing factors such as typography, layout, contrast, headlines, paragraphing, white space, and any other techniques apt to achieve emphasis."

For example, the presentation below of the word benefits and the word disadvantages would not be considered comparable. Although the words are the same point size, the color and contrast with the background make the word benefits much more noticeable than the word disadvantages.
OPDP Frequently Asked Questions (FAQs) (1)

Press Releases

What is the turn-around time for press-releases requested by sponsors?

Generally, there is a 2 working day turn-around for the review of draft press releases when requested by sponsors. This 2 working day turn-around timeframe typically applies to press releases that only reference the prescribing information (PI). For press releases that include references outside the PI and/or require consultation, we will notify the sponsor and treat that press release as a regular launch or non-launch advisory submission.

Pre-distribution Submissions

Does FDA "approve" advertisements and promotional labeling before use by the company?

No, pre-approval of promotional materials is not required except in rare instances. For example,FDA may require pre-approval of promotional materials as part of a compliance action. However,OPDP provides opinions on proposed advertisements and labeling pieces before use upon request by an applicant. Note that accelerated approval products are under a "presubmission" requirement. The accelerated approval regulations require that applicants submit to FDA copies of all promotional materials prior to the intended date of dissemination or publication.

Reminder Advertisements and Labeling

What is a reminder advertisement?

Under 202.1(e)(2)(i), reminder advertisements are identified as an exemption to the advertisement regulations, including the provisions under 202.1(e) to provide a brief summary. Reminder advertisements " . . . call attention to the name of the drug product but do not include indications or dosage recommendations for use of the drug product. . . . and, optionally, information . . . containing no representation or suggestion relating to the advertised drug product." Reminder advertisements cannot make a representation about the product or suggest a use for the product.

What is reminder labeling?

Under 201.100(f), reminder labeling is " . . . labeling which calls attention to the name of the drug product but does not include indications or dosage recommendations for use. . . . and, optionally, information . . . containing no representation or suggestion relating to the drug product." Reminder labeling is exempted from the provisions under 201.100(d) to provide the full prescribing information.

Does FDA limit the amount of money that can be spent on reminder advertisements or reminder labeling pieces or regulate the types of objects (such as pens, cups, calendars, etc.) that can be used as reminder advertisements or reminder labeling pieces?

FDA regulations do not limit how much money companies may spend on reminder advertisements and labeling pieces, nor do the regulations limit the types of objects that can be used. The regulations, however, limit the type of information that can be presented in reminder advertisements and labeling pieces,written information,and ingraphics, design, or some other visual representation.

Miscellaneous Questions

Are the advertising and labeling procedures for orphan drugs and regular NDA products the same?

(Video) Informing and Refining the Prescription Drug Promotion Research Agenda


Return to the Office of Prescription Drug Promotion (OPDP)


What needs to be submitted to OPDP? ›

The applicant shall submit specimens of mailing pieces and any other labeling or advertising devised for promotion of the drug product . . . .

How long does it take FDA to review OPDP? ›

While review timeframes for certain submissions may require more than 45 days in the immediate future, the FDA is working hard to review the majority of submissions within 45 days and to achieve overall completion percentages that are similar to those observed in the past.

What types of promotion does OPDP regulate? ›

The OPDP is responsible for promotional labeling and advertising, which are both used to help sell prescription drugs. Prescription drug advertising includes ads placed in magazines, journals, periodicals, and newspapers as well as those broadcast on television, radio, and by way of telephone communication systems.

What are the responsibilities of OPDP? ›

OPDP reviewers have the responsibility for reviewing prescription drug advertising and promotional labeling to ensure that the information contained in these promotional materials is not false or misleading.

What does a drug have to prove to be approved? ›

FDA approves a drug only after review of extensive testing showing that a drug will provide the benefits described in its labeling, and that those outweigh its risks.

What requirements a drug must fulfill before it is approved? ›

Drug approval usually requires two adequate and well-controlled studies demonstrating that the drug is effective and studies that show it is safe for its intended use. The requirement to demonstrate safety and efficacy prior to approval results from two laws promulgated in 1938 and 1962.

What are the four stages of drug approval? ›

Information For
  • Step 1: Discovery and Development.
  • Step 2: Preclinical Research.
  • Step 3: Clinical Research.
  • Step 4: FDA Drug Review.
  • Step 5: FDA Post-Market Drug Safety Monitoring.
Jan 4, 2018

How hard is it to get FDA approval? ›

Only about ten percent of potential drugs make it through the rigorous process to become FDA approved. Despite these challenges, researchers remain hard at work to develop new safe and effective medications.

Can a drug be approved after Phase 2? ›

A confirmatory phase II trial, which need not be randomized if an active control is not available, can provide sufficient evidence to convince regulatory authorities to grant accelerated approval, and the process can be completed in three years or less.

What are the four main tools of promotion? ›

The four main tools of promotion are advertising, sales promotion, public relation and direct marketing.
  • Advertising. Advertising is defined as any form of paid communication or promotion for product, service and idea. ...
  • Sales Promotion. ...
  • Public Relations. ...
  • Direct Marketing.

What are the 4 types of promotion? ›

The promotions mix is often divided into four categories: advertising, digital selling, sales promotion and public relations. Each of these promotion methods has their own role in generating revenue for a company.

What are the 5 elements of promotion? ›

A promotional mix is an allocation of resources among five primary elements:
  • Advertising.
  • Public relations or publicity.
  • Sales promotion.
  • Direct marketing.
  • Personal selling.

Who is responsible for approving cosmetics before they can be marketed? ›

The two most important laws pertaining to cosmetics marketed in the United States are the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Fair Packaging and Labeling Act (FPLA) . FDA regulates cosmetics under the authority of these laws.

Who has the authority to give the proprietary name of a drug? ›

The brand name is developed by the company requesting approval for the drug and identifies it as the exclusive property of that company. When a drug is under patent protection, the company markets it under its brand name.

What is the purpose of drug inspector? ›

Drug Inspectors are specialists who monitor a drug's safety, utility performance, and consistency from the time it is manufactured until it is sold in a retail outlet. Drug Inspectors, also known as quality control inspectors who ensure that medicines are suitable for human consumption.

How much money does it take to get a drug approved? ›

In an analysis of the drug development costs for 98 companies over a decade, the average cost per drug developed and approved by a single-drug company was $350 million. But for companies that approved between eight and 13 drugs over 10 years, the cost per drug went as high as $5.5 billion.

What is the average length of time for drug approval? ›

Normally, the FDA is allotted 10 months to review new drugs, whereas, under priority review, that time is shortened to 6 months.

What is the timeline for drug approval? ›

The FDA team has 60 days to review the NDA and determine if it will be filed for further review. CDER expects to review and act on at least 90% of NDAs for standard drugs no later than 10 months after the applications are received. The review goal is six months for priority drugs.

What are the four most important parameters governing drug disposition? ›

Four basic processes explain the disposition of drugs through the body: absorption, distribution, metabolism, and excretion. These processes are affected by chemical properties of the drug, patient-specific physiology, body composition, developmental maturation, and pathophysiology relating to disease state.

What are the 3 phases an investigational drug goes through prior to submitting a new drug application? ›

Phase 1 studies (typically involve 20 to 80 people). Phase 2 studies (typically involve a few dozen to about 300 people). Phase 3 studies (typically involve several hundred to about 3,000 people). The pre-NDA period, just before a new drug application (NDA) is submitted.

What are 5 things you need to know about the drug approval process? ›

A pharmaceutical company seeking FDA approval to sell a new prescription drug must complete a five-step process: discovery/concept, preclinical research, clinical research, FDA review and FDA post-market safety monitoring.

What are the three 3 main methods of classifying drugs? ›

Drugs can be categorised by the way in which they affect our bodies:
  • depressants – slow down the function of the central nervous system.
  • hallucinogens – affect your senses and change the way you see, hear, taste, smell or feel things.
  • stimulants – speed up the function of the central nervous system.
Jun 21, 2021

What is the most critical stage in drug discovery? ›

Preclinical Toxicology Testing and IND Application. Preclinical testing analyzes the bioactivity, safety, and efficacy of the formulated drug product. This testing is critical to a drug's eventual success and, as such, is scrutinized by many regulatory entities.

What is the quickest FDA approval? ›

Fast Track designation must be requested by the drug company. The request can be initiated at any time during the drug development process. FDA will review the request and make a decision within sixty days based on whether the drug fills an unmet medical need in a serious condition.

How often does the FDA deny approval? ›

So in reality, the FDA approval rate is more like 96%. Eliminating BioMedTracker's counting of multiple uses for the same drug means FDA approved 23 drugs and rejected 1, Merck 's anesthesia antidote, Bridion. Again, that means 19 of 20 new drug applications were approved.

What is the difference between 510K and PMA? ›

What's the difference between a 510K vs PMA? 510(k) clearance is authorisation from the FDA to market a medium-risk medical device, while PMA (premarket approval) is required for more high-risk and novel products.

Why do most drugs fail in Phase 2? ›

Failures in phase II testing overall usually occur because: 1) previously unknown toxic side effects occur (50%); 2) the trials show insufficient efficacy to treat the medical condition being tested (30%); or 3) commercial viability looks poor (15%) (10).

How long does a Phase 2 trial take? ›

A Phase II clinical trial lasts about 2 years. Volunteers sometimes receive different treatments. For example, a phase II trial could have 2 groups. Group 1 – People who receive the usual treatment for the condition.

Is Phase 3 the last phase? ›

Phase 3 is the final phase before a treatment receives FDA approval. Following FDA approval, a treatment goes through Phase 4. This phase involves the largest group of participants. It can last for several years as researchers continue to monitor the efficacy and safety of the treatment.

What are the three keys to promotion? ›

That's the foolproof formula for getting ahead and/or promoted.
How FC Barcelona Manager Xavi Hernandez Measures Up Against Ronald Koeman After 67 Games
  • Keep your word - do what you say you'll do. ...
  • Do it when you say you will do it. ...
  • Underpromise, but overdeliver - deliver work on the previously agreed on terms.
Jan 15, 2020

What are the 3 critical factors of effective promotion? ›

In fact, coming up with attractive promotions has become a bigger deal than ever.
Three Steps to Effective Sales Promotions
  • Target your effort. ...
  • Plan your incentive. ...
  • Know what you want to achieve.
Feb 1, 2010

Which promotional tool is most effective? ›

Numerous studies have shown that calendars and notepads are the most effective promotional giveaways. The reason for this is that they are used every day, meaning that people are consistently being reminded of your brand.

What are the two bases of promotion? ›

Seniority and merit are the basis of promotion. Promotion can be referred as shifting of employees from one job position to other with higher level of authority. On the basis of seniority and merit, the employees are promoted to a higher job positio with increase in compensation or salary.

What are the 6 strategies used in promotion? ›

Every company can target a unique audience depending on the products and services they offer. There are seven promotional categories, namely direct marketing, sales promotion, digital marketing, personal selling, general advertising, public relations, and sponsorships.

What are the two major forms of promotion? ›

There are two main types of promotion:
  • Persuasive promotion attempts to persuade the consumer that he or she needs the product.
  • Informative promotion attempts to give information about the product, usually in an impressive sounding way. This is often used by the Government, for example to inform people of new laws.

What is the basic rule of promotion? ›

Promotion shall mean movement of an employee from a post in a lower grade to a post in the next higher grade along the line of promotion in his discipline, as prescribed in these rules. Jumping of scale(s) shall not be allowed, save in specific case(s) for Selection Posts, as may be specified in these Rules.

What are the main principles of promotion? ›

The two important principles that are followed in making promotion are the principle of Merit and the principle of Senioety. Both of these have some positive as well as negative aspects. The best way is to combine the merit principle with seniority and make promotions on the basis of merit-cum-seniority.

What permission and licenses are required to make cosmetics? ›

According to Drug and Cosmetics Act, 1940, in India, for the manufacturing of cosmetic product, the following licenses are required: License on form 32 is issued for manufacture/ sale distribute of cosmetics and,Form no. 31 should be submitted.

What are the Labelling requirements for cosmetics? ›

The label should include manufacturer details, manufacturer license number, the product's manufacturing date, and the manufacturing batch number. The label should include the ingredients added to the cosmetic product. Registration Certificate no.

What certification is required for cosmetics? ›

ISO 22716 is an international standard of good manufacturing practices (GMP) for the cosmetics manufacturing industry and describes the basic principles of applying GMP in a facility that produces finished cosmetic products.

What are the five 5 rights of drug administration? ›

One of the recommendations to reduce medication errors and harm is to use the “five rights”: the right patient, the right drug, the right dose, the right route, and the right time.

What is Form 25 and 28 in pharma? ›

Guidelines For Grant Of Additional Products Permissions Under The Licence In Form-25 & FORM-28. The following Documents/Details To Be Submitted: 1. Duly filled additional product proforma duly signed by the licensee viz Proprietor/Partner/Managing Director/Authorised Signatory.

Can a drug have multiple proprietary names? ›

So, for example, the drug infliximab (generic name) is also known as Remicade (brand name). Some drugs are sold in a generic form as well as in a branded form. If several companies market a drug, it will have several different brand names.

What is the highest salary of drug inspector? ›

UPSC Drug Inspector gross salary for UP DI: Rs. 9300-34800/- Other allowances as per government rules. Grade pay 4600/- Level 7. At level 7, the starting wage is 44900 rupees.

How many samples of a product are required to be taken by the drugs inspector? ›

Provided further that where the drug or cosmetic is made up in containers of small volume, instead of dividing a sample as aforesaid, the Inspector may, and if the drug or cosmetic be such that it is likely to deteriorate or be otherwise damaged by exposure shall, take three or four, as the case may be, of the said ...

What are the supportive documents required for the submission of pharmaceutical dossier? ›

Product, Free Sale Certificate, Letter of Authorization, Company certifications and Prescribing Information.

What information must be provided in the new drug application? ›

(1) The name and address of the applicant; the date of the NDA; the NDA number if previously issued (for example, if the NDA is a resubmission or an amendment or supplement); the name of the drug product, including its established, proprietary, code, and chemical names; the dosage form and strength; the route of ...

What must a drug sponsor submit for every new drug for approval from the FDA? ›

The drug sponsor formally asks FDA to approve a drug for marketing in the United States by submitting an NDA. An NDA includes all animal and human data and analyses of the data, as well as information about how the drug behaves in the body and how it is manufactured.

What must be included in a drug advertisement? ›

What must product claim ads tell you?
  • At least one approved use for the drug.
  • The generic name of the drug.
  • All the risks of using the drug. Under certain circumstances, ads can give only the most important risks. For more detail, see brief summary and adequate provision.
Jun 19, 2015

What are the three parts of a dossier? ›

  • Device description. The dossier should include the following device descriptive information: ...
  • Product specification. ...
  • Reference to similar and previous generations of the device. ...
  • Risk analysis and control summary.

What is module 3 of the dossier? ›

Module 3 of CTD refers to quality part. It covers relevant chemical and pharmaceutical information about the QUALITY of medicinal product, its active substances and excipients (including data for biological/biotechnological products).

What should not be included in a dossier? ›

Workload summaries should not include evaluative comments. Administrative, clinical, and extension duties should be distinguished from other service commitments. The summary should explain what counts towards research, teaching, and service activities.

What are 6 items that need to be included when documenting medications? ›

Department of Family Relations
  • Identify the right patient. ...
  • Verify the right medication. ...
  • Verify the indication for use. ...
  • Calculate the right dose. ...
  • Make sure it's the right time. ...
  • Check the right route.

What 3 features are new drugs tested for? ›

Three features new drugs are tested for are safety, efficacy, dosage.

What are the five steps of new drug discovery? ›

Information For
  • Step 1: Discovery and Development.
  • Step 2: Preclinical Research.
  • Step 3: Clinical Research.
  • Step 4: FDA Drug Review.
  • Step 5: FDA Post-Market Drug Safety Monitoring.
Jan 4, 2018

How long after the approval of a drug must the sponsor keep records? ›

For Investigational Device Exemption (IDE) research, the FDA requires the investigator or sponsor to maintain the records “for a period of 2 years after the latter of the following two dates: The date on which the investigation is terminated of completed, or the date that the records are no longer required for purposes ...

What are the three names that can be assigned to a drug? ›

Naming a Drug. A marketed drug has three names: a chemical name, a generic name, and a brand name.

How many phases does it take to get a drug approved? ›

There are three primary phases of the approval process: pre-clinical trials, clinical trials, and new drug application review.

What are the 3 requirements for advertisements? ›

Advertising and Marketing Basics

Under the law, claims in advertisements must be truthful, cannot be deceptive or unfair, and must be evidence-based.

What are the 5 important factors in drug administration? ›

Most health care professionals, especially nurses, know the “five rights” of medication use: the right patient, the right drug, the right time, the right dose, and the right route—all of which are generally regarded as a standard for safe medication practices.

What are 3 things that must be included on a written medication prescription? ›


For a pharmacist to dispense a controlled substance, the prescription must include specific information to be considered valid: Date of issue. Patient's name and address. Patient's date of birth.


1. FDA Communication During Drug Development (4/14) REdI 2017
(U.S. Food and Drug Administration)
2. Cracking the Code for Clinical Pharmacology-Related Prescription Drug Labeling (6/9) Labeling 2017
(U.S. Food and Drug Administration)
(wip games)
4. Understanding the ECTD System of Ad Promo Compliance
(wip games)
6. NDA and BLA Application Review Process (6of15) REdI Annual Conference – May 29-30, 2019
(U.S. Food and Drug Administration)
Top Articles
Latest Posts
Article information

Author: Pres. Lawanda Wiegand

Last Updated: 03/08/2023

Views: 6561

Rating: 4 / 5 (71 voted)

Reviews: 86% of readers found this page helpful

Author information

Name: Pres. Lawanda Wiegand

Birthday: 1993-01-10

Address: Suite 391 6963 Ullrich Shore, Bellefort, WI 01350-7893

Phone: +6806610432415

Job: Dynamic Manufacturing Assistant

Hobby: amateur radio, Taekwondo, Wood carving, Parkour, Skateboarding, Running, Rafting

Introduction: My name is Pres. Lawanda Wiegand, I am a inquisitive, helpful, glamorous, cheerful, open, clever, innocent person who loves writing and wants to share my knowledge and understanding with you.